TG Ther­a­peu­tics with­draws U2 ap­pli­ca­tion — and its com­po­nen­t's ap­provals — one week be­fore ad­comm

The biotech sec­tor moves in mys­te­ri­ous ways.

TG Ther­a­peu­tics on Fri­day vol­un­tar­i­ly with­drew its BLA and sup­ple­men­tal NDA for the blood can­cer com­bo pro­gram U2 …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER